Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 18;10(8):e0004572.
doi: 10.1371/journal.pntd.0004572. eCollection 2016 Aug.

The Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine Tuberculosis

Aseem Pandey  1   2   3 , Ana Cabello  2 , Lavoisier Akoolo  2 , Allison Rice-Ficht  2   4 , Angela Arenas-Gamboa  2 , David McMurray  1 , Thomas A Ficht  2 , Paul de Figueiredo  1   2   3
Affiliations
Review

The Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine Tuberculosis

Aseem Pandey et al. PLoS Negl Trop Dis. .

Abstract

Vaccination of humans and animals with live attenuated organisms has proven to be an effective means of combatting some important infectious diseases. In fact, the 20th century witnessed tremendous improvements in human and animal health worldwide as a consequence of large-scale vaccination programs with live attenuated vaccines (LAVs). Here, we use the neglected zoonotic diseases brucellosis and bovine tuberculosis (BTb) caused by Brucella spp. and Mycobacterium bovis (M. bovis), respectively, as comparative models to outline the merits of LAV platforms with emphasis on molecular strategies that have been pursued to generate LAVs with enhanced vaccine safety and efficacy profiles. Finally, we discuss the prospects of LAV platforms in the fight against brucellosis and BTb and outline new avenues for future research towards developing effective vaccines using LAV platforms.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Lee NH, Lee JA, Park SY, Song CS, Choi IS, et al. (2012) A review of vaccine development and research for industry animals in Korea. Clin Exp Vaccine Res 1: 18–34. 10.7774/cevr.2012.1.1.18 - DOI - PMC - PubMed
    1. Enright FM, Araya LN, Elzer PH, Rowe GE, Winter AJ (1990) Comparative histopathology in BALB/c mice infected with virulent and attenuated strains of Brucella abortus. Vet Immunol Immunopathol 26: 171–182. - PubMed
    1. Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC (2009) Brucellosis: the case for live, attenuated vaccines. Vaccine 27 Suppl 4: D40–43. 10.1016/j.vaccine.2009.08.058 - DOI - PMC - PubMed
    1. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, et al. (2014) Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58: 470–480. 10.1093/cid/cit790 - DOI - PubMed
    1. (1980) Live attenuated measles vaccine. EPI Newsl 2: 6 - PubMed

Publication types

MeSH terms

LinkOut - more resources